Увійти

Готові списки джерел за темами / Radio frequency ablation; liver cancer; liver metastases / Статті в журналах

Статті в журналах з теми "Radio frequency ablation; liver cancer; liver metastases"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Radio frequency ablation; liver cancer; liver metastases.

Автор: Grafiati

Опубліковано: 10 грудня 2022

Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-44 статей у журналах для дослідження на тему "Radio frequency ablation; liver cancer; liver metastases".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Hirata, Masaru. "Comparison Between Radio Frequency Ablation Therapy and Liver Resection for Liver Metastasis from Colorectal Cancer." Gastroenterology 152, no. 5 (April 2017): S295. http://dx.doi.org/10.1016/s0016-5085(17)31273-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Livraghi, Tito, S. Nahum Goldberg, Luigi Solbiati, Franca Meloni, Tiziana Ierace, and G. Scott Gazelle. "Percutaneous Radio-frequency Ablation of Liver Metastases from Breast Cancer: Initial Experience in 24 Patients." Radiology 220, no. 1 (July 2001): 145–49. http://dx.doi.org/10.1148/radiology.220.1.r01jl01145.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Gwak, Ji Hun, Bo-Young Oh, Ryung Ah Lee, Soon Sup Chung, and Kwang Ho Kim. "Clinical Applications of Radio-Frequency Ablation in Liver Metastasis of Colorectal Cancer." Journal of the Korean Society of Coloproctology 27, no. 4 (2011): 202. http://dx.doi.org/10.3393/jksc.2011.27.4.202.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Hirata, Masaru. "Su1221 Comparison Between Radio Frequency Ablation Therapy and Liver Resection for Liver Metastasis From Colorectal Cancer." Gastroenterology 142, no. 5 (May 2012): S—453. http://dx.doi.org/10.1016/s0016-5085(12)61713-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Hirata, Masaru. "S1283 Effect of Radio Frequency Ablation Therapy for Liver Metastasis From Colorectal Cancer." Gastroenterology 138, no. 5 (May 2010): S—220. http://dx.doi.org/10.1016/s0016-5085(10)60999-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Hirata, Masaru. "Tu1534 - Comparable Effect of Radio Frequency Ablation Therapy to Liver Resection for Liver Metastasis from Colorectal Cancer." Gastroenterology 154, no. 6 (May 2018): S—954—S—955. http://dx.doi.org/10.1016/s0016-5085(18)33219-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Pissas, Marie-Hélène, Sebastien Carrere, Lise Roca, Pierre-Emmanuel Colombo, Martin Bertrand, Olivia Sgarbura, Fabienne Portales, et al. "Prolonged survival after two-stage resection of advanced colorectal liver metastases: Impact of an intensified chemotherapy." Journal of Clinical Oncology 33, no. 3_suppl (January 20, 2015): 748. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.748.

Повний текст джерела

Анотація:

748 Background: Patients with advanced colorectal liver metastases (CRLM) experience poor prognosis. The impact of two-stage resection (TSR) after downstaging by chemotherapy is still controversial. Methods: Data on 899 patients with CRLM in a single institution during a 9-year period (2004–2013) were prospectively collected. We used intent-to-treat analysis to evaluate the survival of patients who underwent TSR associated with intensified chemotherapy before and between the two surgical stages. Results: 73 patients were eligible for the first stage of TSR. In this population, 54 patients underwent an intensified chemotherapy based on FOLFIRINOX (26 patients) or a standard chemotherapy associated with cetuximab or bevacizumab (28 patients). The first surgical stage was a clearance of the left liver in 56% of cases. An average of two radio-frequency ablations and two wedge resections were necessary. The post-operative morbidity of the first stage was 18%. 78% of patients received chemotherapy between the two stages. The average interval between two stages was 228 days (36-1561). 68% of TSR patients completed the second stage. The second resection was mainly a standard right lobectomy (32%). Morbidity after the second resection was 12%. One patient died post-operatively because of post operative liver failure. Median overall survival of patients who completed TSR was 48 months. In contrast, there was no survival advantage for patients who underwent only the first stage because of progression (median overall survival: 19 months) (p = 0.0003). The median overall survival of the whole population was 43 months and the median recurrence-free survival was 15 months. Conclusions: Intensified chemotherapy in association with TSR allows excellent outcome in patients with advanced CRLM. Chemotherapy delivered between the two surgical stages is responsible for an important waiting time but could contribute to a better control of the evolution of the disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

MASUDA, TOSHIRO, GEORGIOS ANTONIOS MARGONIS, NIKOLAOS ANDREATOS, JAEYUN WANG, SAMUEL WARNER, MUHAMMAD BILAL MIRZA, ANASTASIOS ANGELOU, et al. "Combined Hepatic Resection and Radio-frequency Ablation for Patients with Colorectal Cancer Liver Metastasis: A Viable Option for Patients with a Large Number of Tumors." Anticancer Research 38, no. 11 (November 2018): 6353–60. http://dx.doi.org/10.21873/anticanres.12993.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Zagoria, Ronald J., Y. M. Michael, Perry Shen, and Edward A. Levine. "Complications from Radio frequency Ablation of Liver Metastases." American Surgeon 68, no. 2 (February 2002): 204–9. http://dx.doi.org/10.1177/000313480206800221.

Повний текст джерела

Анотація:

The objective of this study is to evaluate complications from radiofrequency ablation of liver metastases. Eighty-one liver tumors in 38 consecutive patients were treated with radiofrequency ablation. All patients had one to six metastases treated in a single session. Eight patients underwent radiofrequency ablation intraoperatively after laparotomy and the remaining 30 patients were treated percutaneously with CT or ultrasound guidance. A total of 43 radiofrequency ablation procedures were studied. There was one (2%) mortality related to a hepatic abscess development 8 days after the procedure. One patient (3%) required a blood transfusion. Three patients (8%) developed severe upper abdominal or pleuritic chest pain that persisted several days after the procedure. We conclude that radiofrequency ablation of liver metastases is associated with a low rate of serious complications (two of 38; 5%). Complications requiring treatment usually develop several days after the procedure.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Gillams, A. R., and W. R. Lees. "Radio-frequency ablation of colorectal liver metastases in 167 patients." European Radiology 14, no. 12 (July 27, 2004): 2261–67. http://dx.doi.org/10.1007/s00330-004-2416-z.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Trigg, Nadia, Manish Patel, Amar Hamad, C. Feria, and Charles Berkelhammer. "Cholangitis Complicating Percutaneous Radio-Frequency Ablation RFA] of Liver Metastases." American Journal of Gastroenterology 100 (September 2005): S125. http://dx.doi.org/10.14309/00000434-200509001-00309.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Livraghi, T., S. N. Goldberg, F. Monti, A. Bizzini, S. Lazzaroni, F. Meloni, S. Pellicanò, L. Solbiati, and G. S. Gazelle. "Saline-enhanced radio-frequency tissue ablation in the treatment of liver metastases." Radiology 202, no. 1 (January 1997): 205–10. http://dx.doi.org/10.1148/radiology.202.1.8988212.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

MIGIHASHI, RYUJI. "Study of radio- frequency ablation therapy for the liver cancer." Kanzo 40, no. 12 (1999): 677–78. http://dx.doi.org/10.2957/kanzo.40.677.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Norén, A., P. Sandström, K. Gunnarsdottir, B. Ardnor, B. Isaksson, G. Lindell, and M. Rizell. "Identification of Inequalities in the Selection of Liver Surgery for Colorectal Liver Metastases in Sweden." Scandinavian Journal of Surgery 107, no. 4 (April 25, 2018): 294–301. http://dx.doi.org/10.1177/1457496918766706.

Повний текст джерела

Анотація:

Background: Liver resection for colorectal liver metastases offers a 5-year survival rate of 25%–58%. This study aimed to analyze whether patients with colorectal liver metastases undergo resection to an equal extent and whether selection factors play a role in the selection process. Material and Methods: Data were retrieved from the Swedish Colorectal Cancer Registry (2007–2011) for colorectal cancer and colorectal liver metastases. The patients identified were linked to the Swedish Registry of Liver and Bile surgery and the National Patient Registry to identify whether liver surgery or ablative treatment was performed. Analyses for age, sex, type of primary tumor and treating hospital (university, county, or district), American Society of Anesthesiologists class, and radiology for detection of metastatic disease were performed. Results: Of 28,355 patients with colorectal cancer, 21.6% (6127/28,355) presented with liver metastases. Of the patients with liver metastases, 18.5% (1134/6127) underwent liver resection or ablation. The cumulative proportion of liver resection/ablation was 4% (1134/28,355) of all colorectal cancer. If “not bowel resected” were excluded, the proportion slightly increased to 4.7% (1134/24,262). Around 15% of the patients with metastases were registered as referrals for liver surgery. In a multivariable analysis patients treated at a university hospital for primary tumor were more frequently surgically treated for liver metastases (p < 0.0001). Patients with liver metastases from rectal cancer (p < 0.0001) and men more often underwent liver resection (p = 0.006). A difference was found between health-care regions for the frequency of liver surgery (p < 0.0001). Patients >70 years and those with American Society of Anesthesiologists class >2 underwent liver resection less frequently. Magnetic resonance imaging of the liver was more often used in diagnostic work-up in men. Conclusion: Patients with colorectal liver metastases are unequally treated in Sweden, as indicated by the low referral rate. The proximity to a hepatobiliary unit seems important to enhance the patient’s chances of being offered liver surgery.

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Bonatti, H., G. Bodner, P. Obrist, O. Bechter, G. Wetscher, and D. Oefner. "Skin Implant Metastasis after Percutaneous Radio-Frequency Therapy of Liver Metastasis of a Colorectal Carcinoma." American Surgeon 69, no. 9 (September 2003): 763–65. http://dx.doi.org/10.1177/000313480306900906.

Повний текст джерела

Анотація:

Percutaneous radio-frequency ablation (RFA) of liver tumors has been reported to be an effective approach. Skin implant metastases have been described after RFA of hepatocellular carcinoma. A 56-year-old man underwent resection of the transverse colon for an adenocarcinoma (pT3N2M0) following by adjuvant chemotherapy. He developed multiple liver metastases and underwent RFA. Six weeks after RFA, the patient noticed a painful skin lesion at the entrance side of the probe in the right upper abdominal quadrant. Ultrasound examination and computed tomography scan revealed an intracutaneous tumor of 2-cm diameter. The tumor was excised and revealed a metastasis of the previously described adenocarcinoma. CPT-11 monotherapy was started; however, due to tumor progression, the patient died 35 months after colonic resection and 10 months after RFA. This is the first case of an implant skin metastasis after RFA of secondary liver tumors. Although RFA is a promising option in the palliation of such tumors, such rare complications have to be considered.

Стилі APA, Harvard, Vancouver, ISO та ін.

16

WISSNIOWSKIJR, T., J. HAENSLER, T. BERNATIK, D. SCHUPPAN, E. HAHN, and D. STROBEL. "38 Activation of tumor specific T lymphocytes after radio-frequency ablation in patients with liver metastases." Hepatology 38 (2003): 174. http://dx.doi.org/10.1016/s0270-9139(03)80081-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Arch-Ferrer, J. E., J. K. Smith, S. Bynon, D. E. Eckhoff, M. T. Sellers, K. I. Bland, and M. J. Heslin. "Radio-Frequency Ablation in Cirrhotic Patients with Hepatocellular Carcinoma." American Surgeon 69, no. 12 (December 2003): 1067–71. http://dx.doi.org/10.1177/000313480306901209.

Повний текст джерела

Анотація:

Current surgical treatments for hepatocellular carcinoma (HCC) include radio-frequency ablation (RFA), resection, and orthotropic liver transplant (OLT). RFA is particularly attractive in these high-risk patients because surgery is associated with high mortality and there is a relative scarcity of organs available for those in need of transplants. This study was performed to evaluate the management of cirrhotic patients with HCC undergoing RFA at a single Western institution. A retrospective study from March 1999 to June 2002 was performed to evaluate the clinicopathologic and treatment-related variables in cirrhotic patients with HCC. Forty-nine lesions in 26 patients with HCC and cirrhosis underwent RFA. Data was analyzed for safety and overall survival as the main endpoints. The mean age was 60.4 ± 11 years, 19 patients were male, 5 had hepatitis B virus, and 19 had hepatitis C virus. The Child classification was 26 per cent, 39 per cent, and 35 per cent for A, B, and C; the number of lesions was 1 in 62 per cent, 2 in 23 per cent, and more than 2 in 15 per cent. The approach was laparoscopic in 58 per cent, percutaneous in 15 per cent, and open in 27 per cent. There were no mortalities and only 1 complication. Average hospital stay was 2.7 ± 2 days. Subsequent to RFA, 9 patients underwent an OLT within a median of 4.1 months. The median follow-up of the whole group was 13 months and the disease-free survival 9.3 months. Tumor recurrence was identified in 3 previously ablated lesions, nonablated liver in 11, and as pulmonary metastases in 3. Overall survival (P = 0.03) was prolonged for those treated with RFA + OLT over RFA alone. We conclude that RFA is a safe ablative technique in high-risk cirrhotic patients with HCC. This technique may provide a bridge to OLT; however, it remains to be proven whether it prolongs survival in those who do not undergo OLT.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Solbiati, L., T. Ierace, S. N. Goldberg, S. Sironi, T. Livraghi, R. Fiocca, G. Servadio, et al. "Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients." Radiology 202, no. 1 (January 1997): 195–203. http://dx.doi.org/10.1148/radiology.202.1.8988211.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Tan, A., J. Pape, P. Lykoudis, and B. Davidson. "Radio-frequency ablation for treatment of NET liver metastases: assessment of utilisation at a single tertiary centre." HPB 20 (September 2018): S359. http://dx.doi.org/10.1016/j.hpb.2018.06.2602.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Becker, D., Johannes M. Hänsler, Deike Strobel, and Eckart G. Hahn. "Percutaneous ethanol injection and radio-frequency ablation for the treatment of nonresectable colorectal liver metastases – techniques and results." Langenbeck's Archives of Surgery 384, no. 4 (August 1999): 339–43. http://dx.doi.org/10.1007/pl00008077.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Becker, D., Johannes M. Hänsler, Deike Strobel, and Eckart G. Hahn. "Percutaneous ethanol injection and radio-frequency ablation for the treatment of nonresectable colorectal liver metastases – techniques and results." Langenbeck's Archives of Surgery 384, no. 4 (1999): 339. http://dx.doi.org/10.1007/s004230050211.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Solbiati, L. "Percutaneous ultrasound-guided radio frequency ablation of HCC and liver metastases: results and long-term 7-year follow-up." Ultrasound in Medicine & Biology 29, no. 5 (May 2003): S48. http://dx.doi.org/10.1016/s0301-5629(03)00240-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Lencioni, R., O. Goletti, N. Armillotta, A. Paolicchi, M. Moretti, D. Cioni, F. Donati, et al. "Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle: results of a pilot clinical trial." European Radiology 8, no. 7 (September 2, 1998): 1205–11. http://dx.doi.org/10.1007/s003300050536.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Wissniowski, T. T., J. Hansler, D. Schuppan, T. Bernatik, E. G. Hahn, and D. Strobel. "275 Activation of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases." Journal of Hepatology 40 (January 2004): 85–86. http://dx.doi.org/10.1016/s0168-8278(04)90275-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Haensler, Johannes M., Deike Strobel, Axel Wein, Marianne Pavel, Eckhart G. Hahn, and Dirk Becker. "Percutaneous ultrasound guided radio frequency tissue ablation (RFTA) with a new applicator type-treatment of hepatocellular carcinoma (HCC) and liver metastases." Gastroenterology 118, no. 4 (April 2000): A518. http://dx.doi.org/10.1016/s0016-5085(00)84201-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Goldberg, S. N., L. Solbiati, P. F. Hahn, E. Cosman, J. E. Conrad, R. Fogle, and G. S. Gazelle. "Large-volume tissue ablation with radio frequency by using a clustered, internally cooled electrode technique: laboratory and clinical experience in liver metastases." Radiology 209, no. 2 (November 1998): 371–79. http://dx.doi.org/10.1148/radiology.209.2.9807561.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Hänsler, Johannes. "Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases." World Journal of Gastroenterology 12, no. 23 (2006): 3716. http://dx.doi.org/10.3748/wjg.v12.i23.3716.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Beppu, T., T. Masuda, T. Ishiko, H. Hayashi, S. Sugiyama, K. Doi, H. Takamori, K. Kanemitsu, M. Hirota, and H. Baba. "Radio-frequency ablation (RFA) is equivalent in therapeutic effect but safer compared to microwave coagulation therapy (MCT) for hepatocellular carcinoma." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 15064. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.15064.

Повний текст джерела

Анотація:

15064 Background: Radio-frequency ablation (RFA) and microwave coagulation therapy (MCT) have been developed as a useful locoregional treatment for hepatocellular carcinoma (HCC). It is still unclear which ablation therapy is superior for the patients with HCC, from the viewpoint of not only short term but also long term outcome. Methods: Between January 1991 and December 2005, 430 patients with HCC were treated with ablation therapy (230 RFA and 200 MCT) in our institution. Enroll criteria of this therapy were as follows; 1) unresectable HCCs, 2) each smaller than 3 cm, 3) up to three nodules, 4) without vascular invasion. Either percutaneous (P), endoscopic (E) or open (O) approach was selected individually based on location, size, number, or other factors. Treatment was repeated until complete ablation of HCC. Results: 1. Proportion of Child B or C was 62% and 60%; Stage III or IV was 56% and 58% in the patients with RFA and MCT, respectively. 2. Average tumor size and tumor number was 27mm/2.5 and 26mm/1.9 in the two groups. 3. Approaches were P: 55%, E: 33%, O: 12% in RFA and P: 48%, E: 30%, O: 22% in MCT. 4. Number of treatment was 1.1 in RFA and 1.2 in MCT. 5. Recurrence rate at the therapeutic site was 8% in RFA and 12% in MCT. Especially, endoscopic RFA provided a quite low recurrence rate (3%). 6. Cumulative 5-year survival was 52% versus 45% in the two groups. 7. Complication rate was significantly lower in RFA (5%) compared to MCT (11%). Intraabdominal tumor seeding (1% in MCT) and liver abscess formation (4% in MCT) was never encountered in RFA. Conclusions: Radio-frequency ablation for hepatocellular carcinoma is a safer procedure and can provide a similar favorable long- term prognosis compared to microwave coagulation therapy. No significant financial relationships to disclose.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Reinhardt, Martin, Philipp Brandmaier, Daniel Seider, Marina Kolesnik, Sjoerd Jenniskens, Roberto Blanco Sequeiros, Martin Eibisberger, et al. "A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors: Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT)." Contemporary Clinical Trials Communications 8 (December 2017): 25–32. http://dx.doi.org/10.1016/j.conctc.2017.08.004.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Barkholt, Lisbeth, Rimma Danielsson, Bertil Calissendorff, Leif Svensson, Reza Malihi, Mats Remberger, Mehmet Uzunel, Anders Th??rne, and Olle Ringd??n. "Indium???111-Labelled Donor-Lymphocyte Infusion by way of Hepatic Artery and Radio-Frequency Ablation against Liver Metastases of Renal and Colon Carcinoma after Allogeneic Hematopoietic Stem-Cell Transplantation." Transplantation 78, no. 5 (September 2004): 697–703. http://dx.doi.org/10.1097/01.tp.0000129807.53523.97.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Larsen, Stein G., Svein Dueland, M. Goscinski, Sonja Steigen, Eva Hofsli, Kjersti Flatmark, and Halfdan Sorbye. "Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 3565. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3565.

Повний текст джерела

Анотація:

3565 Background: Patients with metastatic colorectal cancer (mCRC) and mutations in BRAF V600E (mutBRAF) or KRAS (mutKRAS) have a worse prognosis after liver or lung surgery/ablation, whereas the impact of microsatellite instability (MSI-H) has not been well studied. Few patients with mutBRAF receive liver or lung surgery (1-4%), whereas mutBRAF is present in 5-12% of mCRC trial patients and in up to 20% of the general mCRC population. The frequency and prognostic role of mutBRAF, mutKRAS and MSI has not been well studied after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases from colorectal cancer. Methods: The Norwegian Radium Hospital is the only center offering CRS and HIPEC in Norway. From 2004 to 2015 257 patients with histology proven peritoneal metastasis from colorectal cancer, appendiceal cancer excluded, was consecutively enrolled. Molecular analyses of KRAS, BRAF and MSS/MSI in mutBRAF were done. Fourteen patients were excluded due to missing tumour blocks (7), unsuccessful analysis (4) and other malignant disease (1). Results: 180 of 243 patients obtained complete cytoreductive surgery and received HIPEC for 90 minutes with Mitomycin C (45-70mg). Median survival for the 180 patients was 47 months and 5-year survival rate 40.1%. Median disease-free survival was 10 months. mutBRAF was found in 23.4% of cases, mutKRAS 35.1% and double-wild type 41.5%. mutBRAF with MSS was found in 16.4%, mutBRAF with MSI-H in 7.0%. 3-year disease free survival (DFS) and median overall survival (OS) was 38.9% and 59 months with mutBRAF with MSI-H, significantly higher compared to 24.2% and 30 months in patients with double wild type, 13.2 % and 41 months in mutKRAS and 17.9% and 22 months in mutBRAF with MSS. Conclusions: A surprisingly high frequency of mutBRAF was seen in mCRC patients after CRS and HIPEC for peritoneal metastatic disease. Patients with mutBRAF and MSI-H had a significantly better DFS and OS after CRS and HIPEC. DFS for patients with mutBRAF and MSS was numerically lower but not statistically different from patients with mutKRAS or double wild type.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Reghupaty, Saranya Chidambaranathan, and Devanand Sarkar. "Current Status of Gene Therapy in Hepatocellular Carcinoma." Cancers 11, no. 9 (August 28, 2019): 1265. http://dx.doi.org/10.3390/cancers11091265.

Повний текст джерела

Анотація:

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer related deaths world-wide. Liver transplantation, surgical resection, trans-arterial chemoembolization, and radio frequency ablation are effective strategies to treat early stage HCC. Unfortunately, HCC is usually diagnosed at an advanced stage and there are not many treatment options for late stage HCC. First-line therapy for late stage HCC includes sorafenib and lenvatinib. However, these treatments provide only an approximate three month increase in survival. Besides, they cannot specifically target cancer cells that lead to a wide array of side effects. Patients on these drugs develop resistance within a few months and have to rely on second-line therapy that includes regorafenib, pembrolizumab, nivolumab, and cabometyx. These disadvantages make gene therapy approach to treat HCC an attractive option. The two important questions that researchers have been trying to answer in the last 2–3 decades are what genes should be targeted and what delivery systems should be used. The objective of this review is to analyze the changing landscape of HCC gene therapy, with a focus on these two questions.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Du, Yian, and Pengfei Yu. "Conversion chemotherapy combined with surgical treatment of unresectable advanced gastric cancer." Journal of Clinical Oncology 33, no. 3_suppl (January 20, 2015): 189. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.189.

Повний текст джерела

Анотація:

189 Background: Local advanced gastric cancer which could not receive R0 resection, or gastric cancer with single distant metastasis usually received palliative chemotherapy or entered into various clinical trials, and surgery usually roled as a symptomatic treatment. This study is to investigate the efficacy and safety of PCF chemotherapy combined with surgery in the treatment of these patients. Methods: From 2007.8 to 2012.8, 78 cases of local advanced gastric cancer which can not be treated with R0 resection(T4N2~3M0) or gastric cancer with single distant metastases(M1) were prospectively analysed. Patients were treated with 2~4 cycles of combined chemotherapy with paclitaxel (150mg/m2,d1), cisplatin(25mg/m2, d1~3) and 5-fluorouracil (750 mg/m2, d1~3) ( repeated every 3 weeks), and were then treated with cytoreductive surgery: mainly treated with radical resection of gastric tumor, combined with extended lymph node dissection, pancreaticoduodenal resection, colon resection, ovariectomy, liver resection and tumor radio frequency, followed by another 2~4 cycles of postoperative PCF chemotherapy.The treatment completion rate, patients’ tolerance and overall survival time were analyzed. Results: 56 patients (71.8%) accomplished chemotherapy and surgical resection as planned. 47 cases had R0 resection(60.3%). Grade 3/4 toxic effects included bone marrow suppression(24.4%) and gastrointestinal reaction(37.2%), the overall response rate (CR+PR) was 73.1%(CR 2 cases, PR 55 cases). Survival analysis: the median survival time was 23.4 months. 1-year and 3-year survival rate was 68.1% and 33.5%. The OS of patients with surgical resection was much longer than that of the non-surgery group.(36.1 VS 10.0 months, P<0.01). The OS of local advanced group was 38.6 months, and was significantly longer than 20.7 months of the distant metastasis group (P<0.01), however, it had no significant difference compared to 31.3 months of the distant metastasis group with R0 resection. Conclusions: PCF chemotherapy combined with surgical resection were safe and effective, and can make survival benefits for patients with local advanced gastric cancer or gastric cancer with single distant metastasis.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Xiangdong, Cheng. "PCF chemotherapy combined with surgical treatment of advanced gastric cancer." Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 113. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.113.

Повний текст джерела

Анотація:

113 Background: Local advanced gastric cancer that could not receive R0 resection or gastric cancer with distant metastasis usually received palliative chemotherapy or entered into a number of clinical trials, and surgery usually roled as a symptomatic treatment. This study is to investigate the efficacy and safety of PCF chemotherapy combined with surgery in the treatment of these patients. Methods: From July 2008 to February 2011, 72 cases of local advanced gastric cancer that cannot be treated with R0 resection (T4N2~3M0) or gastric cancer with single organ metastases (M1) were prospectively analysed. Patients received 2-4 cycles of PCF chemotherapy (PTX 150mg/m2, d1, CDDP 25mg/m2, d1-3, CF 250 mg/m2, d1-3,5-FU 750 mg/m2, d1-3, repeated every 3 weeks), then the primary and metastatic tumor were treated with cytoreductive surgery: mainly treated with radical resection of gastric tumor, combined with D3 and D4 lymph node dissection, pancreaticoduodenal resection, colon resection, ovariectomy, peritoneal resection, liver resection, and tumor radio frequency, followed with another 2-4 cycles of PCF chemotherapy. The treatment completion rate, patients’ tolerance, and overall survival (OS) time were analyzed. Results: 50 patients (69.4%) accomplished chemotherapy and surgical resection as planned. 42 cases had R0 resection (58.3%). The postoperative complication rate was 6.0%. Grade 3/4 toxic effects included bone marrow suppression (30.6%) and gastrointestinal reaction (40.3%), the overall response rate (CR+PR) was 72.2%. Survival analysis: the median survival time was 23.5 months. 1-year and 2-year survival rate was 67.0% and 47.0%. The OS of patients with surgical resection was much longer than that of the non-surgery group. (30.2 vs. 8.9 months) (p <0.01). The OS of local advanced group was 30.3 months, and was significantly longer than 17.6 months of the distant metastasis group (p <0.01); however, it had no significant difference compared to 28.2 months of the distant metastasis group with R0 resection. Conclusions: PCF chemotherapy combined with surgical resection were safe and effective, and can make survival benefits for patients with local advanced gastric cancer or gastric cancer with single organ metastasis.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Stefanou, Amalia J. "Surgical and Interventional Management of Lung Metastasis: Surgical Assessment, Resection, Ablation, Percutaneous Interventions." Clinics in Colon and Rectal Surgery, November 29, 2022. http://dx.doi.org/10.1055/s-0042-1758823.

Повний текст джерела

Анотація:

AbstractThe lungs are the second most common site of metastases for colorectal cancer after the liver. Pulmonary metastases can be identified at the time of diagnosis of the primary tumor, or metachronously. About 20% of patients with colorectal cancer will develop pulmonary metastases. The best options for treatment include a multidisciplinary treatment approach consisting of surgical resection whenever possible, and chemotherapy. Surgical options most often include minimally invasive segmentectomy or wedge resection, while patients unable to have surgery may benefit from radio frequency ablation or radiation treatment. Prognosis is dependent on preoperative carcinoembryonic antigen level, number, and location of metastatic lesions, and resectability of primary tumor. Overall, pulmonary metastases are best treated by complete resection whenever possible.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Appalanaido, Gokula Kumar, Sheikh Izzat Bin Zainal-Abidin Bahajjaj, Syadwa Abdul Shukor, Muhammad Zabidi Ahmad, and Ho Cho Hao Francis. "Case Report—Staged brachytherapy achieving complete metabolic response in unresectable oligometastatic colorectal cancer to the liver." Oxford Medical Case Reports 2021, no. 4 (April 1, 2021). http://dx.doi.org/10.1093/omcr/omab016.

Повний текст джерела

Анотація:

ABSTRACT Liver is the most common site for metastasis from colorectal cancer (CRC). Non-surgical treatment options for oligometastatic CRC confined to the liver which represents an intermediate state in the metastatic cascade are fast expanding. Currently, several liver-directed local therapeutic options are available, such as hepatic arterial infusion (HAI) therapy, radio-frequency ablation (RFA), transarterial chemoembolization (TACE), stereotactic body radiotherapy and high dose rate brachytherapy (HDRBT). Many factors such as patient’s fitness, liver function (LF), tumour size, location of the tumour in the liver and scheduling of systemic therapy need to be considered when selecting patients for surgery or local liver-directed therapy. This case report illustrates a successful local treatment with staged HDRBT for a large and unresectable, liver only oligometastatic disease from CRC. This patient underwent 4 cycles of chemotherapy (FOLFOX 4) followed by primary tumour resection and first stage of HDRBT to liver for a residual 14 cm tumour after the chemotherapy. After completing a further 4 cycles of chemotherapy with the same regimen, the tumour remained stable at 8 cm. She underwent a second stage of HDRBT to the same lesion and a repeat PET-CT scan done 8 weeks after the second HDRBT showed complete metabolic response. To our knowledge, this is the largest CRC metastatic liver lesion that has been successfully treated with HDRB.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Ye, Changkong, Wenyan Zhang, Zijuan Pang, and Wei Wang. "Efficacy of liver cancer microwave ablation through ultrasonic image guidance under deep migration feature algorithm." Pakistan Journal of Medical Sciences 37, no. 6-WIT (August 4, 2021). http://dx.doi.org/10.12669/pjms.37.6-wit.4885.

Повний текст джерела

Анотація:

Objective: To explore the therapeutic effects of ultrasound-guided microwave ablation and radio frequency ablation for liver cancer patients. Methods: Seventy-eight patients with microwave ablation were rolled into the experimental group and 56 patients with radio frequency ablation were in the control group. This study was conducted from March 1, 2019 to June 30, 2020 in our hospital. Based on Convolutional Neural Networks (CNN) and Migration feature (MF), a new ultrasound image diagnosis algorithm CNNMF was constructed, which was compared with AdaBoost and PCA-BP based on Principal component analysis (PCA) and back propagation (BP), and the accuracy (Acc), specificity (Spe), sensitivity (Sen), and F1 values of the three algorithms were calculated. Then, the CNNMF algorithm was applied to the ultrasonic image diagnosis of the two patients, and the postoperative ablation points, complications and ablation time were recorded. Results: The Acc (96.31%), Spe (89.07%), Sen (91.26%), and F1 value (0.79%) of the CNNMF algorithm were obviously larger than the AdaBoost and the PCA-BP algorithms (P<0.05); in contrast with the control group. The number of ablation points in the experimental group was obviously larger, and the ablation time was obviously shorter (P<0.05); the experimental group had one case of liver abscess and two cases of wound pain after surgery, which were both obviously less than the control group (four cases; five cases) (P<0.05) Conclusion: In contrast with traditional algorithms, the CNNMF algorithm has better diagnostic performance for liver cancer ultrasound images. In contrast with radio frequency ablation, microwave ablation has better ablation effects for liver cancer tumors, and can reduce the incidence of postoperative complications in patients, which is safe and feasible. doi: https://doi.org/10.12669/pjms.37.6-WIT.4885 How to cite this:Riaz A, Sughra U, Jawaid SA, Masood J. Measurement of Service Quality Gaps in Dental Services using SERVQUAL in Public Hospitals of Rawalpindi. Pak J Med Sci. 2021;37(6):1693-1698. doi: https://doi.org/10.12669/pjms.37.6-WIT.4885 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

"Percutaneous Us-Guided Radio-Frequency Tissue Ablation of Liver Metastases: Treatment and Follow-Up in 16 Patients." Journal of Diagnostic Medical Sonography 13, no. 2 (March 1997): 103–4. http://dx.doi.org/10.1177/875647939701300216.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Wissniowski, TTill, D. Schuppan, M. Ocker, D. Strobel, T. Bernatik, M. Frieser, EG Hahn, and J. Hänsler. "ACTIVATION OF TUMOR SPECIFIC T LYMPHOCYTES AFTER RADIO-FREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND COLORECTAL LIVER METASTASES." Ultraschall in der Medizin - European Journal of Ultrasound 26, S 1 (September 14, 2005). http://dx.doi.org/10.1055/s-2005-917471.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Huang, Wei-Hsuan, Chee-Kong Chui, and Stephen K. Y. Chang. "Minimizing Invasiveness of Liver Resection Using an Integrated Tissue Ablation and Division Device With Blood Flow Sensing." Journal of Medical Devices 7, no. 4 (September 24, 2013). http://dx.doi.org/10.1115/1.4025181.

Повний текст джерела

Анотація:

Liver cancer is the fifth most common cancer. Liver resection or hepatectomy has been performed to remove the cancerous portion of the liver organ. This paper reports an integrated surgical mechatronic device that minimizes blood loss during tissue resection and prevents excessive tissue ablation. The novel device integrates radio-frequency electrodes to induce coagulation to the blood vessels, a laser Doppler sensor to detect the stoppage of blood flow, and a retractable knife blade to divide the ablated tissue. Finite element simulation was used to improve upon the placement design of electrodes. Effectiveness of this device in reducing the invasiveness of tissue division was demonstrated with in vitro and in vivo animal experiments.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Singletary, S. E. "Applications of radiofrequency ablation in the treatment of breast cancer." Breast Cancer Online 8, no. 9 (September 2005). http://dx.doi.org/10.1017/s1470903105003743.

Повний текст джерела

Анотація:

Physicians are testing minimally invasive ablation techniques to determine if they will be acceptable substitutes for surgical removal of primary breast tumors. In radiofrequency ablation (RFA), frictional heating of the tissue is caused by the rapid movement of ions attempting to follow a high frequency alternating current moving between two electrodes. Localization of a small electrode in the tumor is accomplished under ultrasound guidance, and a larger electrode pad is placed on the outside of the body. Five pilot studies have demonstrated that RFA can effectively ablate tumors up to 3 cm in size. In addition to treating small primary tumors, RFA may also be useful for consolidation therapy after lumpectomy, for treatment of inoperable tumors in end-stage patients, for treatment of locally advanced disease as a substitute for neoadjuvant chemotherapy, and for treatment of breast cancer metastases, such as bone, liver, and kidney. Clinical trials are needed to assess treatment outcomes and to monitor the long-term fate of ablated tissue.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Zheng, Hui, Feng Zhang, Wayne Monsky, Hongxiu Ji, Weizhu Yang, and Xiaoming Yang. "Interventional Optical Imaging-Monitored Synergistic Effect of Radio-Frequency Hyperthermia and Oncolytic Immunotherapy." Frontiers in Oncology 11 (January 24, 2022). http://dx.doi.org/10.3389/fonc.2021.821838.

Повний текст джерела

Анотація:

PurposeTo develop a new interventional oncology technique using indocyanine green (ICG)-based interventional optical imaging (OI) to monitor the synergistic effect of radiofrequency hyperthermia (RFH)-enhanced oncolytic immunotherapy.Materials and MethodsThis study included (1) optimization of ICG dose and detection time-window for intracellular uptake by VX2 tumor cells; (2) in-vitro confirmation of capability of using ICG-based OI to assess efficacy of RFH-enhanced oncolytic therapy (LTX-401) for VX2 cells; and (3) in-vivo validation of the interventional OI-monitored, intratumoral RFH-enhanced oncolytic immunotherapy using rabbit models with orthotopic liver VX2 tumors. Both in-vitro and in-vivo experiments were divided into four study groups (n=6/group) with different treatments: (1) combination therapy of RFH+LTX-401; (2) RFH alone at 42°C for 30 min; (3) oncolytic therapy with LTX-401; and (4) control with saline. For in-vivo validation, orthotopic hepatic VX2 tumors were treated using a new multi-functional perfusion-thermal radiofrequency ablation electrode, which enabled simultaneous delivery of both LTX-401 and RFH within the tumor and at the tumor margins.ResultsIn in-vitro experiments, taking up of ICG by VX2 cells was linearly increased from 0 μg/mL to 100 μg/mL, while ICG-signal intensity (SI) reached the peak at 24 hours. MTS assay and apoptosis analysis demonstrated the lowest cell viability and highest apoptosis in combination therapy, compared to three monotherapies (P<0.005). In in-vivo experiments, ultrasound imaging detected the smallest relative tumor volume for the combination therapy, compared to other monotherapies (P<0.005). In both in-vitro and in-vivo experiments, ICG-based interventional optical imaging detected a significantly decreased SI in combination therapy (P<0.005), which was confirmed by the “gold standard” optical/X-ray imaging (P<0.05). Pathologic/laboratory examinations further confirmed the significantly decreased cell proliferation with Ki-67 staining, significantly increased apoptotic index with TUNEL assay, and significantly increased quantities of CD8 and CD80 positive cells with immunostaining in the combination therapy group, compared to other three control groups (P<0.005).ConclusionsWe present a new interventional oncology technique, interventional optical imaging-monitored RFH-enhanced oncolytic immunotherapy, which may open new avenues to effectively manage those patients with larger, irregular and unresectable malignancies, not only in liver but also the possibility in other organs.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Vaidya, Nikhil, Marco Baragona, Valentina Lavezzo, Ralph Maessen, and Karen Veroy. "Tuning the Pennes Perfusion Rate to Model Large Vessel Cooling Effects in Hepatic Radiofrequency Ablation." Journal of Biomechanical Engineering 144, no. 8 (March 11, 2022). http://dx.doi.org/10.1115/1.4053909.

Повний текст джерела

Анотація:

Abstract Radio frequency ablation (RFA) has become a popular method for the minimally invasive treatment of liver cancer. However, the success rate of these treatments depends heavily on the amount of experience the clinician possesses. Mathematical modeling can help mitigate this problem by providing an indication of the treatment outcome. Thermal lesions in RFA are affected by the cooling effect of both fine-scale and large-scale blood vessels. The exact model for large-scale blood vessels is advection-diffusion, i.e., a model capable of producing directional effects, which are known to occur in certain cases. In previous research, in situations where directional effects do not occur, the advection term in the blood vessel model has been typically replaced with the Pennes perfusion term, albeit with a higher-than-usual perfusion rate. Whether these values of the perfusion rate appearing in literature are optimal for the particular vessel radii in question, has not been investigated so far. This work aims to address this issue. An attempt has been made to determine, for values of vessel radius between 0.55 mm and 5 mm, best estimates for the perfusion rate which minimize the error in thermal lesion volumes between the perfusion-based model and the advection-based model. The results for the best estimate of the perfusion rate presented may be used in existing methods for fast estimation of RFA outcomes. Furthermore, the possible improvements to the presented methodology have been highlighted.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Elgindy, E. M., I. M. F. Montasser, W. E. Saad, and M. A. Ghanem. "Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio as Diagnostic and Prognostic Markers for Hepatitis C Virus – Related Hepatocellular Carcinoma in Egyptian Patients." QJM: An International Journal of Medicine 113, Supplement_1 (March 1, 2020). http://dx.doi.org/10.1093/qjmed/hcaa069.004.

Повний текст джерела

Анотація:

Abstract Background hepatocellular carcinoma (HCC), a highly prevalent and lethal cancer, it is the sixth most common cancer and the third leading cause of cancer-related death worldwide. Aim of the work to evaluate the role of inflammatory markers Neutrophil lymphocyte ratio and Platelet lymphocyte ratio (NLR & PLR) as biomarkers for diagnosis of HCV related HCC. Patients and Methods this study was conducted in tropical medicine department, HCC clinic Ain-shams university hospitals. Our study included 174 candidates who were divided into three groups. Group A included 60 Patients with HCV-related HCC diagnosed according to American Association for the Study of Liver Diseases (AASLD) guidelines; HCC patients were subdivided into three subgroups According to BCLC Results group A included 114 Patients with HCV-related HCC, which was subdivided into three subgroups according to BCLC. Group 1 included 30 patients underwent Radio-frequency ablation (RF), 76.67% of them were males while 23.33% were females with mean age 57.433. Group 2 included 41 patients underwent Trans-arterial chemo-embolization (TACE), 80.49% were males while 19.51% were females with mean age 60.268. Group 3 included 43 Patients with BCLC stage C and D For best supportive care, 76.74% were males while 23.26% were females with mean age 60.372. Male to female ratio in HCC patients was 3.56:1. Conclusion AFP remains the gold standard marker for diagnosis of HCC. NLR and PLR has no role as early prognostic markers for HCC.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!